Skip to main
MRK
MRK logo

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co has demonstrated an optimistic financial outlook, with a projected increase in 1Q 2025 sales to $15.1 billion and earnings per share (EPS) growth to $2.09, reflecting strong operational performance. The company has also been highlighted for its robust international revenues, which exceed those of the U.S. on an ex-FX basis, emphasizing its global market strength. Furthermore, the anticipation of sustained growth from Winrevair, bolstered by favorable trial outcomes for pulmonary arterial hypertension, positions Merck for continued success in the competitive pharmaceutical landscape.

Bears say

Merck & Co. has experienced lower-than-expected volumes for its Welireg product, prompting a downward revision of US revenue estimates for the first quarter and beyond. Furthermore, the company anticipates a significant foreign exchange headwind of approximately $1.3 billion in FY25 revenue due to a 2% impact from currency fluctuations. This combination of reduced product performance and adverse currency effects raises concerns about the overall financial outlook for Merck & Co.

Merck (MRK) has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Hold based on their latest research and market trends.

According to 13 analysts, Merck (MRK) has a Hold consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.